General
Preferred name
IVABRADINE
Synonyms
IVABRADINE HYDROCHLORIDE ()
Ivabradine (D3 Hydrochloride) ()
Ivabradine (D6 hydrochloride) ()
Ivabradine HCl ()
S 16257-2 ()
Ivabradine HCl (Procoralan) ()
Ivabradine (hydrochloride) ()
ivabradine, Jiangsu Hengrui Medicine ()
S 16257-2,S-18982 D6 hydrochloride ()
Corlanor ()
Procoralan ()
S-16257 ()
Ivabradine ()
Corlentor ()
AMG-998 ()
AMG 998 ()
S-16257-2 ()
S 16257 ()
Ivabradine (hydrochloride) ()
Ivabradine-d3 (hydrochloride) ()
P&D ID
PD000477
CAS
149470-58-6
148870-61-5
155974-00-8
148849-67-6
1217809-61-4
Tags
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
2015
2005
Drug Status
approved
Drug indication
Angina pectoris
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION Ivabradine is indicated by the FDA to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. It is also indicated for treatment of stable symptomatic heart failure as a result of dilated cardiomyopathy for pediatric patients 6 months of age or more[FDA Label].
METABOLISM Ivabradine is extensively metabolized by oxidation in the gut and liver by cytochrome P450 3A4 enzyme. Its active metabolite, N-desmethylated derivative, is also metabolized by CYP 3A4. Ivabradine's affinity for CYP 3A4 is low, making it unlikely to affect the metabolism of other drugs; however potent inhibitors or inducers of CYP 3A4 may affect ivabradine's plasma concentration and pharmacodynamic effects and should not be co-administered.;
DESCRIPTION Marketed drugs contain ivabradine hydrochloride (PubChem CID 3045381). (GtoPdb)
DESCRIPTION Stomatin-like protein-3 (STOML3) oligomerization inhibitor (Tocris Bioactive Compound Library)
Compound Sets
27
AdooQ Bioactive Compound Library
A11868
Axon Medchem Screening Library
3495
Cayman Chemical Bioactives
15868
25711
ChEMBL Approved Drugs
CHEMBL471737
CHEMBL2145077
ChEMBL Drugs
CHEMBL471737
CHEMBL2145077
Concise Guide to Pharmacology 2017/18
2357
Concise Guide to Pharmacology 2019/20
2357
Concise Guide to Pharmacology 2021/22
2357
Concise Guide to Pharmacology 2023/24
2357
Drug Repurposing Hub
DrugBank
DB09083
DrugBank Approved Drugs
DB09083
DrugCentral
3312
DrugCentral Approved Drugs
3312
DrugMAP
DM0L594
DrugMAP Approved Drugs
DM0L594
Guide to Pharmacology
2357
MedChem Express Bioactive Compound Library
HY-B0162A
NCATS Inxight Approved Drugs
3H48L0LPZQ
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
ivabradine-hcl-procoralan
TargetMol Bioactive Compound Library
T2535
The Spectrum Collection
Tocris Bioactive Compound Library
6542
ZINC Tool Compounds
ZINC000003805768
External IDs
63
Properties
(calculated by RDKit )
Molecular Weight
468.26
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
10
Ring Count
4
Aromatic Ring Count
2
cLogP
3.31
TPSA
60.47
Fraction CSP3
0.52
Chiral centers
1.0
Largest ring
7.0
QED
0.53
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Adrenergic Receptor
HCN1, HCN3, HCN4
I(f) channel inhibitor
HCN Channel
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Membrane Transporter/Ion Channel
Primary Target
HCN Channels
MOA
Blocker
HCN channel blocker, potassium channel blocker, sodium channel blocker
Indication
angina pectoris
Source data